CURIS

Curis Lifesciences Share Price

 

 

Curis Lifesciences live price: ₹107.25. It opened at ₹108 vs previous close ₹106; intraday high/low: ₹112/₹107. The 50 DMA stands at ₹101.92.

Curis Lifesciences Performance

  • Today's Low
  • ₹107
  • Today's High
  • ₹112
  • 52 Week Low
  • ₹84
  • 52 Week High
  • ₹148
  • Open Price₹108
  • Previous Close₹106
  • Volume12,000
  • 50 DMA₹101.92
  • 100 DMA-
  • 200 DMA-

Investment Returns

  • Over 1 Month + 12.89%
  • Over 3 Month -17.31%
  • Over 6 Month -16.21%
  • Over 1 Year -16.21%

Smart Investing Starts Here Start SIP with Curis Lifesciences for Steady Growth!

Invest Now

Curis Lifesciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 14.2
  • PEG Ratio
  • -
  • Market Cap Cr
  • 87
  • P/B Ratio
  • 4.1
  • Average True Range
  • 4.5
  • EPS
  • 7.55
  • Dividend Yield
  • 0
  • MACD Signal
  • -1.78
  • RSI
  • 61.58
  • MFI
  • 70.82

Curis Lifesciences Financials

Curis Lifesciences Technicals

EMA & SMA

Current Price
₹107.25
+ 1.25 (1.18%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 11
  • 20 Day
  • ₹97.52
  • 50 Day
  • ₹101.92
  • 100 Day
  • -
  • 200 Day
  • -

Resistance and Support

108.6 Pivot Speed
  • R3 116.10
  • R2 114.05
  • R1 110.65
  • S1 105.20
  • S2 103.15
  • S3 99.75

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Curis Lifesciences manufactures pharmaceutical products with a specialization in ophthalmic sterile ointments. The company focuses on producing high-quality, compliant formulations for healthcare needs, supported by dedicated manufacturing capabilities and a growing presence in the domestic pharmaceutical market.

Curis Lifesciences Ltd has an operating revenue of Rs. 148.05 Cr. on a trailing 12-month basis. An annual revenue growth of 38% is outstanding, Pre-tax margin of 17% is great, ROE of 37% is exceptional. The company has a reasonable debt to equity of 46%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 200DMA and around 5% up from its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 96 which is a GREAT score indicating consistency in earnings, a RS Rating of 28 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 30 indicates it belongs to a strong industry group of Medical-Ethical Drugs and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Curis Lifesciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-12-04 Quarterly Results

Curis Lifesciences F&O

Curis Lifesciences Shareholding Pattern

68.03%
0.11%
2.93%
0.11%
13.98%
14.84%

Curis Lifesciences FAQs

Curis Lifesciences share price is ₹107 As on 13 April, 2026 | 03:45

The Market Cap of Curis Lifesciences is ₹86.7 Cr As on 13 April, 2026 | 03:45

The P/E ratio of Curis Lifesciences is 14.2 As on 13 April, 2026 | 03:45

The PB ratio of Curis Lifesciences is 4.1 As on 13 April, 2026 | 03:45

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23